Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

SellasgpsCurativeBAT11 Aug. 28 at 2:44 PM

$ABBV $AZN $JNJ $PFE $SLS Merger Monday’s. Biotech Contrarian Indicators flashing big time today. ✌️🙏❤️‍🩹

0 · Reply

Outcomes Aug. 28 at 1:28 PM

$MRNA $MRK $PFE $JNJ .....how could I forget to copy this group!?

0 · Reply

SellasgpsCurativeBAT11 Aug. 28 at 12:24 PM

$ABBV $AZN $JNJ $PFE $SLS All the Repositioners, traders will be left on the sidelines when the T1 halt hits. Shorts are burying themselves deeper and deeper before liquidation 🔥 ✌️🙏❤️‍🩹

0 · Reply

SellasgpsCurativeBAT11 Aug. 28 at 12:13 PM

$SLS $JNJ $PFE $ABBV $AZN Every passing day starting to look like Data+Deal coming in Consecutive order. ✌️🙏❤️‍🩹

0 · Reply

MrsFroggy Aug. 28 at 10:58 AM

$IBRX $JNJ $MRK $MRNA $PFE

0 · Reply

Outcomes Aug. 28 at 10:42 AM

$IBRX $MRNA $MRK $PFE $JNJ https://x.com/Berlinergy/status/2027713838502547676?s=20

0 · Reply

Outcomes Aug. 28 at 10:41 AM

$IBRX $MRNA $MRK $PFE $JNJ .......mRNA BAD. 'There is not one Oncologist in the United States or Canada that has the guts to say COVID-19 Vaccines cause cancer. Not one.' except: Dr. Pat.....'Turbo-Cancers' PSS knows. https://x.com/blueshot007/status/2089517782639821263?s=20

1 · Reply

Gebinator Aug. 28 at 3:57 AM

$SLS $JNJ

0 · Reply

Gebinator Aug. 28 at 2:07 AM

$SLS $JNJ less than an hour to go!

0 · Reply

SellasgpsCurativeBAT11 Aug. 27 at 11:43 PM

$JNJ $SLS SLS #4 Trending on Stocktwits $15.25 Up $1.52 (11.07%) WHY IT'S TRENDING Sellas Life Sciences (SLS) is seeing high volume and strong upward momentum as retail traders discuss potential sector tailwinds from personalized cancer vaccine discussions and eagerly await upcoming trial data catalysts. 🙏✌️❤️‍🩹

0 · Reply

China approves J&J's oral psoriasis pill, says drugmaker

Aug 24, 2026, 7:12 PM EDT - 3 days ago

FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients

Aug 24, 2026, 6:33 PM EDT - 3 days ago

US FDA expands approval for J&J's drug for rare blood disorder

Aug 24, 2026, 12:20 PM EDT - 3 days ago

Louisiana Jury Issues $10 Million Verdict in Talc-Related Mesothelioma Case Against Johnson & Johnson

2026-08-19T22:09:27.000Z - 8 days ago

Analysts Back Dividend Aristocrats JNJ and LIN Ahead of Q3 Earnings

LIN

2026-08-17T10:16:04.000Z - 11 days ago

Oppenheimer upgrades Intuitive Surgical on lack of U.S. competition

ISRG

Aug 13, 2026, 11:15 PM EDT - 14 days ago

Expert explains why healthcare is a top-performing sector

ABBV AMGN BIIB GILD LLY MRK UNH

Aug 10, 2026, 4:27 PM EDT - 17 days ago

Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

2026-08-07T19:33:43.000Z - 20 days ago

3 ‘Strong Buy’ Dividend Aristocrat Stocks to Grab Right Now to Get Paid in September — 8/7/26

CVX WMT

Aug 6, 2026, 6:23 PM EDT - 21 days ago

Jim Cramer highlights 5 investing themes — and the stocks to buy for each

AMAT AXP COF CRWD GS KLAC LLY

2026-08-06T10:48:29.000Z - 22 days ago

Johnson & Johnson price target raised to $287 from $270 at Guggenheim

Aug 4, 2026, 4:05 PM EDT - 23 days ago

Johnson & Johnson to Participate in the 2026 Wells Fargo Healthcare Conference

Aug 4, 2026, 8:45 AM EDT - 24 days ago

Johnson & Johnson's Executive Vice President Jennifer Taubert to Retire; Tom Cavanaugh Appointed EVP, Worldwide Chairman Innovative Medicine Effective September

Aug 3, 2026, 8:00 AM EDT - 25 days ago

Johnson & Johnson Transcript: Investor update

Aug 2, 2026, 8:00 AM EDT - 26 days ago

Inside J&J's Lab to Create a Simpler Robotic Surgery Device

Jul 30, 2026, 8:30 AM EDT - 4 weeks ago

Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer

Jul 29, 2026, 6:13 PM EDT - 4 weeks ago

Johnson & Johnson Comes to Strategic Agreement with Sail Biomedicines

Jul 29, 2026, 5:42 PM EDT - 4 weeks ago

Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation

Jul 29, 2026, 5:38 PM EDT - 4 weeks ago

Johnson & Johnson lowers 2026 profit forecast

Jul 29, 2026, 5:28 PM EDT - 4 weeks ago

Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset

Jul 29, 2026, 12:01 PM EDT - 4 weeks ago

Explainer: Can J&J finally put the talc litigation behind it?

Jul 28, 2026, 4:31 PM EDT - 4 weeks ago

Johnson & Johnson offers $5.5 billion to settle remaining lawsuits over talc products linked to cancer

Jul 28, 2026, 12:26 PM EDT - 4 weeks ago

Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits

Jul 28, 2026, 1:03 AM EDT - 4 weeks ago

Johnson & Johnson to pay $5.5bn settlement in talc cancer lawsuit

Jul 28, 2026, 12:31 AM EDT - 4 weeks ago

J&J offers $5.5bn to settle baby powder lawsuits

Jul 27, 2026, 9:29 PM EDT - 4 weeks ago

Johnson & Johnson Agrees to Pay $5.5 Billion to Settle Talc Lawsuits

Jul 27, 2026, 6:47 PM EDT - 4 weeks ago

Johnson & Johnson announces $5.5 billion settlement of talc lawsuits

Jul 27, 2026, 6:31 PM EDT - 4 weeks ago

Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation

Jul 27, 2026, 5:45 AM EDT - 4 weeks ago

Robert Kiyosaki sees a brutal depression ahead: 3 stocks that may protect portfolios

NEM WMT

$TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma$

Jul 23, 2026, 8:30 AM EDT - 5 weeks ago

TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma

Jul 22, 2026, 4:33 PM EDT - 5 weeks ago

US judge casts doubt on 69,000 cases alleging J&J talc caused cancer

Jul 22, 2026, 7:21 AM EDT - 5 weeks ago

Johnson & Johnson's robotic surgery device gets US FDA marketing authorization

Jul 22, 2026, 7:00 AM EDT - 5 weeks ago

Johnson & Johnson Receives FDA Market Authorization in the U.S. for its OTTAVA™ Robotic Surgical System

Jul 21, 2026, 6:30 PM EDT - 5 weeks ago

Jim Cramer says this old-school investing concept still wins — even in the AI boom

BNY CVS GS MMM WFC

Jul 16, 2026, 8:11 AM EDT - 6 weeks ago

Johnson & Johnson Announces Collaboration with TIME to Introduce New Healthcare Champion of the Year Award

Jul 16, 2026, 8:00 AM EDT - 6 weeks ago

DePuy Synthes Acquires Expanding Innovations™

Jul 15, 2026, 12:09 PM EDT - 6 weeks ago

J&J Leverages AI and Robots to Target $100 Billion in Annual Revenue

Jul 15, 2026, 8:30 AM EDT - 6 weeks ago

Johnson & Johnson Earnings Call Transcript: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 6 weeks ago

Johnson & Johnson Slides: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 6 weeks ago

Johnson & Johnson Earnings release: Q2 2026

Jul 15, 2026, 8:30 AM EDT - 6 weeks ago

Johnson & Johnson Quarterly report: Q2 2026

Jul 15, 2026, 7:27 AM EDT - 6 weeks ago

ASML, Intel, Johnson & Johnson, and More Stocks That Explain Today's Market

ASML INTC

Jul 15, 2026, 6:35 AM EDT - 6 weeks ago

Johnson & Johnson Hikes Guidance, Stock Falls

Jul 15, 2026, 6:33 AM EDT - 6 weeks ago

Johnson & Johnson Bumps Up Guidance as Sales Rise

Jul 15, 2026, 6:25 AM EDT - 6 weeks ago

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2026

Jul 15, 2026, 6:23 AM EDT - 6 weeks ago

J&J quarterly earnings beat Wall Street estimates on strength of medicines unit

Jul 15, 2026, 6:20 AM EDT - 6 weeks ago

Johnson & Johnson reports Q2 2026 results, raises 2026 outlook

Jul 9, 2026, 1:00 PM EDT - 7 weeks ago

The Big 3: UNH, KO, JNJ

KO UNH

Jul 8, 2026, 7:45 AM EDT - 7 weeks ago

Johnson & Johnson Announces FDA Approval for the Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jul 6, 2026, 6:29 PM EDT - 7 weeks ago

Jim Cramer says these are the 5 stocks to buy during this market rotation

PEP SBUX STZ TJX

Jun 26, 2026, 2:39 PM EDT - 2 months ago

Healthcare stocks have become a haven for investors ditching tech

ABBV ABSI APGE LLY MRNA SNY XBI

Jun 26, 2026, 12:35 PM EDT - 2 months ago

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

Jun 25, 2026, 5:00 AM EDT - 2 months ago

Johnson & Johnson Advances Cardiac Ablation Technology in Europe with Availability of Dual Energy THERMOCOOL SMARTTOUCH SF Platform

Jun 15, 2026, 6:00 AM EDT - 2 months ago

Johnson & Johnson Invests more than $1 Billion to Strengthen U.S. Vision Manufacturing in Jacksonville, Florida

$New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma$

Jun 13, 2026, 6:41 AM EDT - 2 months ago

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

$New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma$

Jun 13, 2026, 6:33 AM EDT - 2 months ago

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

Jun 11, 2026, 7:45 AM EDT - 2 months ago

Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients

Jun 11, 2026, 2:03 AM EDT - 2 months ago

IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies

SellasgpsCurativeBAT11 Aug. 28 at 2:44 PM

$ABBV $AZN $JNJ $PFE $SLS Merger Monday’s. Biotech Contrarian Indicators flashing big time today. ✌️🙏❤️‍🩹

0 · Reply

Outcomes Aug. 28 at 1:28 PM

$MRNA $MRK $PFE $JNJ .....how could I forget to copy this group!?

0 · Reply

SellasgpsCurativeBAT11 Aug. 28 at 12:24 PM

0 · Reply

SellasgpsCurativeBAT11 Aug. 28 at 12:13 PM

$SLS $JNJ $PFE $ABBV $AZN Every passing day starting to look like Data+Deal coming in Consecutive order. ✌️🙏❤️‍🩹

0 · Reply

MrsFroggy Aug. 28 at 10:58 AM

$IBRX $JNJ $MRK $MRNA $PFE

0 · Reply

Outcomes Aug. 28 at 10:42 AM

$IBRX $MRNA $MRK $PFE $JNJ https://x.com/Berlinergy/status/2027713838502547676?s=20

0 · Reply

Outcomes Aug. 28 at 10:41 AM

1 · Reply

Gebinator Aug. 28 at 3:57 AM

$SLS $JNJ

0 · Reply

Gebinator Aug. 28 at 2:07 AM

$SLS $JNJ less than an hour to go!

0 · Reply

SellasgpsCurativeBAT11 Aug. 27 at 11:43 PM

0 · Reply

SellasgpsCurativeBAT11 Aug. 27 at 11:08 PM

$SLS $JNJ Mr. Cavanaugh takes over 9/1/26. Everything lining up to perfection. 🙏✌️❤️‍🩹

0 · Reply

KilroyPicks Aug. 27 at 9:37 PM

$MIST - Rome wasn't built in a day. This drug is a specialty drug with a specific and relatively small patient base less than 1% of the US population. Also, this is Milestone's first drug so they are building relationships from scratch from doctors to the formulary channels. This will take a little longer to build than a drug from say Pfizer & $PFE or J&J $JNJ or Bristol-Myer Squib $BMY , those companies already have the relationships in place.

2 · Reply

Outcomes Aug. 27 at 8:55 PM

$IBRX $MRNA $PFE $JNJ ......'why did I choose this career path? I am seeing so much carnage. I beg you. I am seeing so much autoimmunity developing. I've seen 4 men trying to conceive, not one single functioning sperm.' mRNA BAD. 'It is beyond all reasonable doubt' mRNA causes 'Turbo-cancers. And now, mRNA for cancer treatment. THE ULTIMATE HYPOCRISY. PSS KNOWS. https://x.com/ImBreckWorsham/status/2092973899935858784?s=20 SAVE THE CHILDREN. 🙏

5 · Reply

Gebinator Aug. 27 at 2:38 PM

$SLS $JNJ

3 · Reply

greenrockk Aug. 27 at 2:35 PM

$JNJ easy close at 270

0 · Reply

Wallstfan Aug. 27 at 2:08 PM

$JNJ added $264 and change to my IRA

0 · Reply

NRG8 Aug. 27 at 12:57 PM

$AVGO $V $MA $JNJ $ABBV Do you know of a more undervalued company than BZUN which is profitable, growing and has low debt? BZUN share price is $2.9 and today the company has raised FY28 forecast EPS to $1.79 .

0 · Reply

Galarius Aug. 27 at 12:44 PM

$JNJ $SLS interesting

1 · Reply

Joshoowa Aug. 27 at 12:14 PM

$SLS https://www.jnj.com/health-and-wellness/what-is-acute-myeloid-leukemia $JNJ added this to their website August 17th. Hmmmm. Everything here points to GPS and an acquisition of SLS. Good chance it could be them buying. They don't do things without reason.

1 · Reply

Parlandoconme Aug. 27 at 11:11 AM

$TOMZ Buy time. Easily beating revenue estimates in Q3 according to an insider named Ray. $JNJ $STE $SPCX

0 · Reply

clan Aug. 27 at 5:36 AM

$MNKD $UTHR Oh, btw, Mannkind's Nintedanib DPI, in Ph 2 trial, does NOT have any adverse events! 😀 ... unlike the current 💩-causing OFEV. Made in the U.S.A.! 💪🇺🇲💪 👀 $SPY 👀 $QQQ 👀 $JNJ 👀

0 · Reply

ElliottwaveForecast Aug. 27 at 3:13 AM

$JNJ should continue rally targeting 271.37 or higher within daily bull run against May-2026 low. Short term pullback against 6.22.2026 low should remain supported to continue rally to extend ((5)). Check out the details at https://elliottwave-forecast.com/stock-market/jnj-elliott-wave-bullish-rally-targets-271-37-beyond/ #Elliottwave #JNJ

0 · Reply

Market Cap	650.67B
Revenue (ttm)	94.19B
Net Income (ttm)	26.80B
EPS (ttm)	N/A
PE Ratio	25.15
Forward PE	23.52
Profit Margin	28.46%
Debt to Equity Ratio	0.44

Volume	7,311,300
Avg Vol	7,989,024
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	42%
Beta	0.24
Analysts	Strong Sell
Price Target	$275.42